IMCD N.V.
ROTTERDAM, The Netherlands (9 March 2021) – IMCD N.V. ("IMCD" or "Company"), a leading distributor of speciality chemicals and ingredients, today announces that it has reached an agreement to sell its Nutri Granulations manufacturing asset and associated business to Huber Engineered Materials ("HEM"), a division of J.M. Huber Corporation ("Huber").
"Huber is an important supplier partner for IMCD and we are delighted to reach an agreement on the sale of Nutri Granulations," says Marcus Jordan, Americas President, IMCD. "HEM is a favorable long-term fit for Nutri Granulations and this agreement aligns with IMCD’s strategy to focus on the sales, marketing, and distribution of speciality chemicals and ingredients."
Located in La Mirada, CA, with 22 employees, Nutri Granulations manufactures food grade and USP grade calcium carbonate granulations for the nutraceuticals, food, over-the-counter, and pharmaceuticals markets. It was acquired by IMCD as part of the HORN acquisition in 2018.
"We are thrilled to add Nutri Granulations to our portfolio because their reputation for quality, reliability, and customer focus aligns perfectly with ours", adds Matt O'Brien, Senior Vice President and General Manager for HEM’s Ground Calcium Carbonate strategic business unit. "Also, adding an additional manufacturing site will support supply security and business continuity for our customers."
The closing of the transaction is planned for the end of March 2021.
Attached, please find the press release in pdf format.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom